Cercar

17/04/2023 Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial
Crees, ZD, Rettig, MP, Jayasinghe, RG, Stockerl-Goldstein, K, Larson, SM, Arpad, I, Milone, GA, Martino, M, Stiff, P, Sborov, D, Pereira, D, Micallef, I, Moreno-Jimenez, G, Mikala, G, Coronel, MLP, Holtick, U, Hiemenz, J, Qazilbash, MH, Hardy, N, Latif, T, Garcia-Cadenas, I, Vainstein-Haras, A, Sorani, E, Gliko-Kabir, I, Goldstein, I, Ickowicz, D, Shemesh-Darvish, L, Kadosh, S, Gao, F, Schroeder, MA, Vij, R, DiPersio, JF. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. NATURE MEDICINE. 2023; 29(4)DOI:10.1038/s41591-023-02273-z. PMID:37069359. IF:58.700(Q1/1D).
01/04/2023 Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
Perl A.E., Larson R.A., Podoltsev N.A., Strickland S., Wang E.S., Atallah E., Schiller G.J., Martinelli G., Neubauer A., Sierra J., Montesinos P., Recher C., Yoon S.-S., Maeda Y., Hosono N., Onozawa M., Kato T., Kim H.-J., Hasabou N., Nuthethi R., Tiu R., Levis M.J.. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. Transplantation And Cellular Therapy. 2023; 29(4)DOI:10.1016/j.jtct.2022.12.006. PMID:36526260. IF:3.600(Q1/3D).
01/04/2023 Multiallelic Copy Number Variation in ORM1 is Associated with Plasma Cell-Free DNA Levels as an Intermediate Phenotype for Venous Thromboembolism
Martin-Fernandez, L, Garcia-Martinez, I, Lopez, S, Martinez-Perez, A, Vilalta, N, Plaza, M, Moret, C, Vinuela, A, Brown, AA, Panousis, NI, Buil, A, Dermitzakis, ET, Corrales, I, Souto, JC, Vidal, F, Soria, JM. Multiallelic Copy Number Variation in ORM1 is Associated with Plasma Cell-Free DNA Levels as an Intermediate Phenotype for Venous Thromboembolism. THROMBOSIS AND HAEMOSTASIS. 2023; 123(04)DOI:10.1055/s-0043-1760844. PMID:36696913. IF:5.000(Q1/2D).
14/03/2023 Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era
Mussetti, A, Bento, L, Bastos-Oreiro, M, Sansalvador, BR, Albo, C, Bailen, R, Barba, P, Benzaquen, A, Briones, J, Caballero, AC, Campos, A, Espanol, I, Ferra, C, Lopez, SG, Sierra, PAG, Guerra, LM, Hernani, R, Iacoboni, G, Ubieto, AIJ, Kwon, M, Corral, LL, Lopez-Godino, O, Munoz, MCM, Martinez-Cibrian, N, Gomez, JM, Perez-Ortega, L, Ortf, G, Ortiz-Maldonado, V, Pascual, MJ, Perera, M, Perez, A, Reguera, JL, Sanchez, JM, Sanz, J, Torrent, A, Yanez, L, Varela, R, Echechipia, IC, Caballero, D, Sureda, A. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era. BONE MARROW TRANSPLANTATION. 2023; 58(6)DOI:10.1038/s41409-023-01949-x. PMID:36918682. IF:4.500(Q1/2D).
01/03/2023 T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo
Nunez, Y, Garcia-Leon, A, Falgas, A, Serna, N, Sanchez-Garcia, L, Garrido, A, Sierra, J, Gallardo, A, Unzueta, U, Vazquez, E, Villaverde, A, Mangues, R, Casanova, I. T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo. Pharmaceutics. 2023; 15(3)DOI:10.3390/pharmaceutics15030727. PMID:36986589. IF:4.900(Q1/2D).
01/03/2023 Quantitative PCR for the Diagnosis of HCMV Pneumonia in HSCT Recipients and Other Immunocompromised Hosts
Berengua, C, Martino, R. Quantitative PCR for the Diagnosis of HCMV Pneumonia in HSCT Recipients and Other Immunocompromised Hosts. Hemato. 2023; 4(1)DOI:10.3390/hemato4010008. PMID:. IF:(Q/D).
05/01/2023 One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
Pinana, JL, Vazquez, L, Calabuig, M, Lopez-Corral, L, Martin-Martin, G, Villalon, L, Sanz-Linares, G, Conesa-Garcia, V, Sanchez-Salinas, A, Gago, B, Facal, A, Risco-Galvez, I, Olave, MT, Espigado, I, Lopez-Jimenez, J, Hernandez-Rivas, JA, Avendano-Pita, A, Arroyo, I, Ferrer, E, Garcia-Cadenas, I, Gonzalez-Santillana, C, Roldan-Perez, A, Ferrer, B, Guerreiro, M, Suarez-Lledo, M, Camara, A, Campos-Beltran, D, Navarro, D, Cedillo, A, Sureda, A, Solano, C, Martino, R. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients. Blood Cancer Journal. 2023; 13(1)DOI:10.1038/s41408-022-00778-3. PMID:36599843. IF:12.900(Q1/1D).
01/01/2023 Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols
Barba, P, Morgades, M, Montesinos, P, Gonzalez-Campos, J, Torrent, A, Gil, C, Bernal, T, Tormo, M, Mercadal, S, Novoa, S, Garcia-Cadenas, I, de Llano, MPQ, Cervera, M, Coll, R, Bermudez, A, Amigo, ML, Monsalvo, S, Esteve, J, Garcia-Boyero, R, Novo, A, Rivas, JMH, Cladera, A, Martinez-Sanchez, P, Serrano, J, Artola, MT, Soria, B, Abella, E, Vall-Llovera, F, Bergua, J, Herrera, P, Barrios, D, Ribera, JM. Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols. Hemasphere. 2023; 7(1)DOI:10.1097/HS9.0000000000000810. PMID:36583094. IF:11.900(Q1/1D).